Spanish contract drugmaker Laboratorios Farmacéuticos Rovi has officially planted its flag in Phoenix, taking over an injectable drug manufacturing plant previously owned by Bristol Myers Squibb and locking in years of ongoing work from the pharma giant. The deal keeps production humming at the Valley facility and, according to company filings and local reporting, gives Rovi a meaningful U.S. foothold in the tightly regulated world of sterile injectables.
A Rovi subsidiary paid $18.5 million for the roughly 20.5-acre property, and the sale comes with a five-year manufacturing agreement to keep producing for Bristol Myers Squibb. According to the Phoenix Business Journal, the deal shifts ownership to ROIS Phoenix Inc., Rovi’s U.S. unit, and keeps operations running while the new owner settles in.
Inside the Deal and Production Pact
Rovi told investors that ROIS Phoenix Inc. signed both an Asset Purchase Agreement and a toll-manufacturing contract with Bristol Myers Squibb, with an initial five-year term and minimum payments of $50 million per year, as detailed by ROVI. In its market notice, the company said the acquisition price was “not material” to its balance sheet and that the transaction was expected to wrap up in the first half of 2026. Rovi framed the move as a strategic play to bulk up injectable manufacturing capacity in North America.
Rovi’s U.S. Expansion Play
ROIS, Rovi’s CDMO arm that rebranded last year, has already mapped out a major upgrade. The company plans to install a prefilled-syringe isolator line in 2027 that could add tens of millions of syringe units of annual capacity, positioning the Phoenix facility as a high-capacity injectable hub. Industry coverage notes that the site is already approved for sterile injectables and that Bristol Myers Squibb has invested roughly $100 million there since 2021, giving Rovi a fully regulated, ready-built platform to scale. As reported by Pharma Manufacturing, the acquisition fits neatly into Rovi’s broader injectable-focused strategy.
What This Means for Phoenix
Local economic watchers say the five-year guaranteed work provides near-term revenue certainty and helps preserve jobs tied to the plant, giving Rovi breathing room to invest and court additional clients. The move plugs directly into Phoenix’s growing bioscience and advanced manufacturing ecosystem and could draw in suppliers and specialized workers if Rovi follows through on its planned capacity upgrades. As outlined by the Greater Phoenix Economic Council, investments like this can strengthen and densify the region’s life science cluster.
What to watch next: Rovi’s hiring and permitting announcements, the launch timeline for the new prefilled-syringe line slated for 2027, and whether ROIS can bring in other injectable clients beyond Bristol Myers Squibb. If the company hits its stated timetable, Phoenix could soon host significantly expanded sterile injectable capacity under its new owner.
